Biotech | February 10, 2022
Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
On track to complete the BLA submission in the first half of 2022
On track to complete the BLA submission in the first half of 2022
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
The hospital has recently launched Radionuclide therapy
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
The company will manufacture a cancer immunotherapy product from 2022
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Subscribe To Our Newsletter & Stay Updated
